<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346865</url>
  </required_header>
  <id_info>
    <org_study_id>CVRF2010-10</org_study_id>
    <nct_id>NCT01346865</nct_id>
  </id_info>
  <brief_title>Drug-Eluting Stenting Followed by Cilostazol tREAtment Reduces SErious Adverse Cardiac Events (DECREASE-PCI)</brief_title>
  <official_title>A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With Drug Eluting Stent for Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CardioVascular Research Foundation, Korea</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The DECREASE-PCI trial is a prospective, randomized, placebo controlled, double-blind, phase
      4 study to evaluate efficacy and safety of triple anti-platelet therapy compared with dual
      antiplatelet therapy in patients treated with DES for Coronary Artery Disease.

      The primary objective of this study is to compare the safety and efficacy of triple
      antiplatelet therapy versus dual (standard) antiplatelet therapy in patients treated with
      drug-eluting stent (DES) implantation for the treatment of coronary artery disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Use of drug-eluting stent (DES) has reduced the incidence of restenosis rate and the need for
      repeat revascularization compared to using bare metal stents (BMS). Therefore, DES
      implantation has been default strategy in the treatment of coronary artery disease. However,
      despite use of DES, the restenosis, subsequent repeat revascularization, and associated
      cardiac events (stent thrombosis, myocardial infarction) remain significant clinical problem
      in routine practice, especially complex lesion subsets.

      2110 patients who received successful dug eluting stent implantation will be enrolled at 21
      centers in Korea. Patients meeting inclusion criteria without any exclusion criteria and
      agree to participate in this trial will be randomized 1:1 to a) triple therapy
      (Aspirin+Clopidogrel +Cilostazol) or b) dual therapy group (Aspirin+ Clopidogrel +Placebo).
      All patients will be blindly assigned to cilostazol 100mg (1tablet bid) or matching placebo
      (1tablet bid) as 1:1 ratio and are prescribed for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low Recruitment
  </why_stopped>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Adverse Cardiac and Cerebrovascular Ischemic Events (MACCE)</measure>
    <time_frame>At 1-year time point after PCI</time_frame>
    <description>composite of any death, myocardial infarction, ischemic stroke, target vessel revascularization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Events (MACE)</measure>
    <time_frame>At 1-year time point and yearly up to 3 years after PCI</time_frame>
    <description>Composite of major cardiac adverse events (MACE) including death, Q-MI, Non Q- MI, and target lesion or vessel revascularization
Target vessel revascularization
Target lesion revascularization
Stent thrombosis (definite/probable)
Ischemic stroke
Myocardial infarction
Adverse Events during study periods</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">402</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cilostazol 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dual therapy group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Cilostazol 100mg bid</description>
    <arm_group_label>cilostazol</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 1tablet bid</description>
    <arm_group_label>dual therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Clinical

          1. Patients with angina and documented ischemia or patients with documented silent
             ischemia

          2. Patients who are eligible and has been successfully applied for DES implantation

          3. Age &gt;18 years

          4. Signed written informed consent form prior to study entry

        2. Angiographic

          1. De novo lesion or restenotic lesions

          2. Percent diameter stenosis â‰¥50%

          3. Reference vessel size 2.5 mm by visual estimation

        Exclusion Criteria:

          1. History of bleeding diathesis or coagulopathy (e.g. current use of NSAIDs, Upper GI
             bleeding during the recent 6 months)

          2. Pregnancy or lactation (women who have child-bearing potential)

          3. Known hypersensitivity or contra-indication to contrast agent, heparin, eluted-drug of
             stent

          4. Limited life-expectancy (less than 1 year) due to combined serious disease

          5. Characteristics of lesion 1)Left main disease 2)Graft vessels

          6. Hematological disease (Neutropenia &lt;3000/mm3, Thrombocytopenia &lt;100,000/mm3)

          7. Hepatic dysfunction, liver enzyme (ALT and AST) elevation 3 times normal

          8. Renal dysfunction, creatinine 2.0mg/dL

          9. Contraindication to aspirin, clopidogrel or cilostazol

         10. Stroke (ischemic or hemorrhagic) or transient ischemic attack (TIA) within 6 months.

         11. Planned major surgery within the next 6 months with the need to discontinue
             antiplatelet therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seung-Jung Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine, Asan Medical Center University of Ulsan College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang Univ. Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangneung Asan Hospital</name>
      <address>
        <city>Gangneung</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Yangsan Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Medicine, Asan Medical Center University of Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMA-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.carollo Hospital</name>
      <address>
        <city>Suncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>May 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <last_update_submitted>November 13, 2015</last_update_submitted>
  <last_update_submitted_qc>November 13, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>CardioVascular Research Foundation, Korea</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>M.D., Ph.D.,Professor of Medicine Asan Medical Center, University of Ulsan, College of Medicine</investigator_title>
  </responsible_party>
  <keyword>triple anti-platelet therapy</keyword>
  <keyword>dual antiplatelet therapy</keyword>
  <keyword>DES</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

